United States: Transfer Payments For Offshored Patents Can Invite IRS Scrutiny And Hinder Patent Damages Claims


Tax inversions and the offshoring of intellectual property by U.S. companies grew from an arcane tax law subject to a popular election year issue this autumn. This was partly due to a new IRS program emphasizing the enforcement of existing transfer pricing rules, which are particularly relevant for companies that offshore patents and other IP to foreign corporate entities. Transfer pricing is a significant area of scrutiny for the IRS because transfer payments impact the foreign income of American companies and the amount of tax the U.S. can collect. The IRS emphasis on transfer pricing enforcement is likely to remain after Election Day 2016. Therefore, well-thought-out strategies by tax and IP attorneys for determining transfer payments between U.S. companies and foreign subsidiaries can protect the overall value of the IP assets to the corporate family as well as enable an entity in the corporate family to recover for the damages caused by infringement of offshored patents.


Since the 1990s, American companies have been merging with entities in lower-tax countries and offshoring their IP in exchange for transfer payments to reduce taxes. U.S. corporations have tripled the profits they earn in foreign tax havens by using transfer payments to maximize expenses in the U.S. and maximize income overseas. In response, however, the IRS recently announced its new emphasis on transfer pricing enforcement to address tax avoidance.

In addition, recent Federal Circuit case law has found transfer pricing agreements do not sufficiently reflect the value of the IP transferred. This case law has resulted in dramatically reduced damages for infringement of offshored patents. In Warsaw Orthopedic, Inc. v. Nuvasive, Inc. (Warsaw I), the court held that an offshore patent holder may not obtain the lost profits of a U.S. subsidiary as damages for infringement. This decision was reaffirmed after remand on other grounds in the 2016 case Warsaw Orthopedic, Inc. v. Nuvasive, Inc. (Warsaw II). In Warsaw I, the court also held that while the patentee was entitled to a reasonable royalty for the value of its patents, transfer payments made pursuant to a transfer pricing agreement from a U.S. subsidiary could not be used as a starting place for analyzing the reasonable royalty for the patented technology because the transfer payments did not result from arm's-length negotiations.

Transfer Pricing and Patent Damages

Transfer pricing is the price charged by a company to an offshore subsidiary for intangible property such as patents. See 26 U.S.C. § 482 (allocating income attributed to the transfer of intangible assets between companies). Transfer pricing is a significant area of scrutiny for the IRS because transfer payments impact the foreign income of American companies and the amount of tax the U.S. can collect. To minimize inter-company price manipulation, transfer pricing rules apply an arm's-length standard, requiring IP transactions between subsidiaries be consistent with comparable transactions between unrelated parties. See Treas. Reg. § 1.482-1(a) – (b) (describing the purpose and scope of the arm's-length standard). Therefore, tax inversions invite increased IRS scrutiny of IP transactions because of the complexity of determining arm's-length pricing between related offshore entities.

In a tax inversion, an American company merges with a smaller company in a lower-tax country. Tax inversions drew public attention in 2016, when Pfizer proposed a merger with Allergan to invert to Ireland. Biotechnology and pharmaceutical companies have found that transferring their patents to subsidiaries in lower-tax jurisdictions in exchange for transfer payments can result in profits being taxed at lower rates. However, in addition to increased IRS scrutiny of such patent transfers, the Federal Circuit's 2015 Warsaw I decision could hinder claims for patent damages by a company that has effected a tax inversion, such that its IP is held offshore.

Courts recognize two measures of patent damages: lost profits and reasonable royalties. Warsaw I quoting 35 U.S.C. § 284 (providing for "damages adequate to compensate for infringement, but in no event less than a reasonable royalty"). A patentee may recover lost profits when it can prove that it would have earned those profits in the absence of infringement. See Rite-Hite Corp. v. Kelley Co. (en banc). A reasonable royalty is the alternative measure of damages where a lost profits award is not appropriate or does not fully account for the harm to the patent holder of the infringement. A reasonable royalty, on the other hand, compensates the patentee for the value of what was appropriated (the patented technology). See Warsaw I. This remedy "derives from a hypothetical [arm's-length] negotiation between the patentee and the infringer...." See ResQNet.com, Inc. v. Lansa, Inc.

In an early setback to claims for damages related to infringement of offshored IP, with their 2004 decision in Poly-America, L.P. v. GSE Lining Technology, Inc., the Federal Circuit held that a patent holder may not claim the lost profits of a related U.S. company as its own damages. Poly-America sued GSE for infringement of two patents licensed to Poly-America's sister company, Poly-Flex, which was located in the U.S. GSE conceded infringement, and a jury awarded damages. On appeal, however, the Federal Circuit reversed the district court's damages finding, holding that Poly-America could not claim the lost profits of Poly-Flex because Poly-America did not sell a product embodying the claimed invention, even though it collaborated in such a product's manufacture and sale by Poly-Flex. Although Poly-America was located in the U.S., the Federal Circuit decision would also apply to a foreign patent holder suing for lost profits of a related U.S. company.

Four years later, in Mars, Inc. v. Coin Acceptors, Inc., amended by Mars, Inc. v. Coin Acceptors, Inc. (2009), a patent infringement action related to vending machine technology, the Federal Circuit held that because the plaintiff transferred its entire interest in the asserted patents to its subsidiary in the U.K., the plaintiff was not entitled to recover lost profits and, in fact, lacked standing to sue. On remand, the district court found that the plaintiff could cure standing by transferring ownership of the patents back from its UK subsidiary but the plaintiff was only awarded reasonable royalties of $25 million. Consent Final Judgment After Return of Mandate, Mars, Inc. v. Coin Acceptors, Inc., No. 2:90-CV-00049, No. 428 (D.N.J. Apr. 17, 2009).

The Federal Circuit's Damages Analysis in Warsaw

In 2008, the medical device company Warsaw Orthopedic along with its related company Medtronic Sofamor Danek USA, Inc. (MSD), both located in the U.S., sued Nuvasive for infringement of two patents assigned to Warsaw. Warsaw did not practice the patented technology. Instead, it licensed the technology to its related companies, Medtronic Puerto Rico Operations Co. (M Proc) of Puerto Rico and Medtronic Sofamor Danek Deggendorf, GmBH (Deggendorf) of Germany, which respectively manufactured and sold the patented products to MSD.Deggendorf and M Proc each paid separate royalties to Warsaw on their product sales. Warsaw manufactured non-patented surgical rods and screws ("fixations") for MSD, which packaged them with the patented products into medical kits. At trial, Warsaw attempted to obtain lost profits damages on three sources of income: (1) revenue from the sale of fixations to MSD; (2) royalty payments from M Proc and Deggendorf; and (3) "transfer payments" from MSD to Warsaw to account for the fair market value of property exchanges and implied licenses for various patented technologies between the companies. The district court found that Nuvasive infringed Warsaw's patents and awarded lost profits and a reasonable royalty.

On appeal, the Federal Circuit rejected each of Warsaw's claims for lost profits. The court first noted that a patentee may recover lost profits for convoyed sales (when a non-patented component is sold with a patented product) only if the non-patented component is functionally related to the patented product: "Being sold together merely for 'convenience or business advantage' is not enough." The court found that Warsaw failed to prove the functional relationship necessary for lost profits on convoyed sales of its fixations because including fixations with the patented product was merely for convenience. Therefore, the court rejected the claim of lost profits from sales of the non-patented fixations.

Second, the court noted that under Poly-America, a patentee may not claim the lost profits of a related company as its own damages. "To be entitled to lost profits... the lost profits must come from the lost sales of a product or service the patentee itself was selling." Although Warsaw contended that it was making the sales, and that Deggendorf and M Proc were merely its agents, the evidence did not support this characterization. Therefore, the impact of infringement on Deggendorf's and M Proc's sales was not recoverable as lost profits. The court, however, did not indicate whether Warsaw could have collected lost profits if it had shown that Deggendorf and M Proc were acting as its agents.

Third, the court noted that Warsaw received transfer payments from MSD to reflect the fair market value of property exchanges, management fees and implied licenses regarding other patents. These payments from MSD amounted to 95% of MSD's profits from the sale of the patented products. Regardless, the court found that the decline in the transfer payments was not recoverable as lost profits because Warsaw did not distinguish what percentage of the transfer payments was attributable to the patented technology, as opposed to unrelated transactions. Neither did the transfer pricing agreements distinguish transfer payments on a technology or product basis.

Although the court rejected Warsaw's claims for lost profits, it recognized that Warsaw was at least entitled to a reasonable royalty sufficient to compensate it for the value of the infringed patents under 35 U.S.C. § 284: "the court shall award the claimant damages adequate to compensate for infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer." The court noted that evidence of royalty agreements entered into at arm's-length can be evidence of the value of a patent. But the Court held that royalties and transfer payments paid by related companies are not probative as to a patent's value because such payments do not result from arm's-length negotiations. In Warsaw I, citing Allen Archery, Inc. v. Browning Manufacturing Co., the court rejected agreements between related parties as establishing a royalty rate because the transactions were not arm's-length. Therefore, the transfer payments from MSD and royalties from Deggendorf and M Proc could not be used as a starting place for calculating the percentage of profits attributable to practice of the patented invention.

Takeaways for Patent Owners and Exclusive Licensees

Tax and IP attorneys advising clients on the offshoring of IP in exchange for transfer payments should consider the following:

  • Where the IP offshored is central to the value of a product line and is likely to be enforced against competitors, offshoring it can negatively impact the overall value of the asset to the corporate family. Unless the offshore entity is actually involved in product development, the transfer of the asset is likely to prevent any entity in the corporate family from being able to fully recover for the damages caused by patent infringement.
  • Given that offshoring IP is usually part of a larger corporate transaction, where transfer pricing is set for a business or part of a business, recognize that the transfer pricing agreement that does not break out the value of specific IP assets is likely not going to be considered by a court in setting damages using a reasonable royalty framework. An agreement that does break out the value of specific IP assets could come into evidence if it is in line with industry valuations. If it is not in line with industry valuations, it may be excluded as not reflecting an arm's-length negotiation.
  • The litigation alternatives to admission of the transfer pricing agreement are either to set separate payments in the transfer pricing agreement for the patented aspects of a product versus non-patented features, or to resign oneself to the admission of arguably non-comparable licenses from other sources. In the absence of evidence of valuation for the specific patent assets, courts will consider evidence of comparable licenses.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Sep 2018, Conference, California, United States

We're excited to introduce Women's IP Strategy, a 2-day conference that tackles both the IP, legal as well as broader career development obstacles, risks and rewards for women lawyers working in male-dominant industries.

2 Oct 2018, Webinar, California, United States

This CLE webinar will offer suggestions to litigators to help them comply with the new GDPR during e-discovery.

10 Oct 2018, Webinar, California, United States

For the past years, 3D printing has significantly revolutionized the business industry as it provides innovations and improvement to pre-existing processes.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions